Trials / Completed
CompletedNCT03745157
RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in Japan
A Prospective Non-interventional Study Investigating the Treatment Effect of Switching From Insulin Glargine to Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real World Adult Population With Type 2 Diabetes in Japan
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 246 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to collect information on how Ryzodeg® works in real world participants. Participants will get Ryzodeg® as prescribed to them by the study doctor. The study will last for about 6 to 8 months. The participants will be asked questions about their health and their diabetes treatment as part of their normal study doctor's appointment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Insulin Degludec/Insulin Aspart | Patients will be treated with commercially available Insulin Degludec/Insulin Aspart (Ryzodeg®) in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the treating physician in accordance with the Ryzodeg® label in Japan |
Timeline
- Start date
- 2018-11-21
- Primary completion
- 2019-10-29
- Completion
- 2019-10-29
- First posted
- 2018-11-19
- Last updated
- 2019-12-09
Locations
29 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03745157. Inclusion in this directory is not an endorsement.